Kaydence Pharma

Kaydence Pharma was a development-stage biopharmaceutical company focused on MQ-7, a pharmaceutical formulation of menaquinone-7 (vitamin K2) intended to treat vascular calcification and arterial stiffness associated with subclinical vitamin K deficiency. The company's lead development focus was chronic kidney disease and stable renal transplant recipients, where inactive matrix Gla protein is associated with elevated cardiovascular risk. Kaydence reported a successful FDA pre-IND meeting in January 2019 and described plans to advance MQ-7 into first-in-human studies, but there is no clear evidence that it progressed into registered clinical trials. The company was spun out of NattoPharma in 2017 and was later fully acquired by NattoPharma in 2021. Based on available public information, Kaydence appears to have remained a single-asset, early-stage private company rather than an operating commercial biopharma business.